Egis Pharmaceuticals made a net profit of HUF 18,531 mil with revenues of HUF 132,825 mil in 2012, up by 36.4% and up by 3.01%, respectively, compared to the previous year. This translates into a net margin of 14.0%.
On the operating level, EBITDA reached HUF 30,536 mil, up 19.2% compared to the previous year. Over the last five years, the company's EBITDA has risen 15.9% a year on average.
The company generated cash, defined by a sum of net profit and depreciation, of HUF 28,631 mil or 21.6% of sales. When investments are excluded, free cash flow reached HUF 11,446 mil, or 8.62% of sales in 2012.
In the last five years, the company generated free cash flow of HUF 33,951 mil. That compares to a cumulative net profit of HUF 74,694 mil in the same period.
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
